Protection by Meningococcal Outer Membrane Protein PorA-Specific Antibodies and a Serogroup B Capsular Polysaccharide-Specific Antibody in Complement-Sufficient and C6-Deficient Infant Rats
- 1 May 2006
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 74 (5) , 2803-8
- https://doi.org/10.1128/iai.74.5.2803-2808.2006
Abstract
The relative contributions of antibody-induced complement-mediated bacterial lysis and antibody/complement-mediated phagocytosis to host immunity against meningococcal infections are currently unclear. Further, the in vivo effector functions of antibodies may vary depending on their specificity and Fc heavy-chain isotype. In this study, a mouse immunoglobulin G2a (mIgG2a) monoclonal antibody (MN12H2) to meningococcal outer membrane protein PorA (P1.16), its human IgG subclass derivatives (hIgG1 to hIgG4), and an mIgG2a monoclonal antibody (Nmb735) to serogroup B capsular polysaccharide (B-PS) were evaluated for passive protection against meningococcal serogroup B strain 44/76-SL (B:15:P1.7,16) in an infant rat infection model. Complement component C6-deficient (PVG/c − ) rats were used to assess the importance of complement-mediated bacterial lysis for protection. The PorA-specific parental mIgG2a and the hIgG1 to hIgG3 derivatives all induced efficient bactericidal activity in vitro in the presence of human or infant rat complement and augmented bacterial clearance in complement-sufficient HsdBrlHan:WIST rats, while the hIgG4 was unable to do so. In C6-deficient PVG/c − rats, lacking complement-mediated bacterial lysis, the augmentation of bacterial clearance by PorA-specific mIgG2a and hIgG1 antibodies was impaired compared to that in the syngeneic complement-sufficient PVG/c + rat strain. This was in contrast to the case for B-PS-specific mIgG2a, which conferred similar protective activity in both rat strains. These data suggest that while anti-B-PS antibody can provide protection in the infant rats without membrane attack complex formation, the protection afforded by anti-PorA antibody is more dependent on the activation of the whole complement pathway and subsequent bacterial lysis.Keywords
This publication has 25 references indexed in Scilit:
- Naturally Acquired Passive Protective Activity against Neisseria meningitidis Group C in the Absence of Serum Bactericidal ActivityInfection and Immunity, 2004
- Recombinant Neisseria meningitidis Transferrin Binding Protein A Protects against Experimental Meningococcal InfectionInfection and Immunity, 2001
- The infant rat model adapted to evaluate human sera for protective immunity to group B meningococciVaccine, 1999
- Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccineVaccine, 1996
- Hereditary C6 deficiency in a strain of PVG/c ratsClinical and Experimental Immunology, 1994
- Killing of Meningococci by Neutrophils: Effect of Vaccination on Patients with Complement DeficiencyThe Journal of Infectious Diseases, 1994
- Vaccination and the Role of Capsular Polysaccharide Antibody in Prevention of Recurrent Meningococcal Disease in Late Complement Component-Deficient IndividualsThe Journal of Infectious Diseases, 1993
- SERUM OPSONINS TO GROUP B MENINGOCOCCIActa Pathologica Microbiologica Scandinavica Series C: Immunology, 1987
- Killing of Neisseria meningitidis by Human Neutrophils: Implications for Normal and Complement-Deficient IndividualsThe Journal of Infectious Diseases, 1987
- HUMAN IMMUNITY TO THE MENINGOCOCCUSThe Journal of Experimental Medicine, 1969